Drug Trial Radar · NCT07867288
Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HTX-001
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
10
Planned (sponsor's estimate)
Start
Oct 30, 2026
Primary completion
Mar 2027
Study completion Mar 2027
Sponsor
- Lead sponsor
- Haya Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of HTX-001 in human adult participants.
Conditions
- Nonobstructive Hypertrophic Cardiomyopathy
Interventions
HTX-001Drug
HTX-001 is an investigational antisense oligonucleotide (ASO)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and TolerabilityTime frame: Through Day 43
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Lahey Clinic
Boston, Massachusetts · Recruiting
Saint Luke's Health System
Kansas City, Missouri · Recruiting
The Lindner Research Center at The Christ Hospital
Cincinnati, Ohio · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.